ArticleMolecular biology reports2024
Protective effect of oleuropein on the brain tissue in D-Galactose-induced aging in rat model.
Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exercise-Induced Activation of IGF-1/mTOR Signaling and Hippocampal BDNF/PGC-1α Expression Reverses Age-Related Motor Decline.International neurourology journal · 2026Article
- Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026Review
- Oleaceae plants: a source of metabolites with atheroprotective potential.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOleuropein (OLE) has the potential to reduce oxidative stress and inflammation. So, in the present investigation, we explored the protective effect of OLE on brain aging induced by d-galactose (D-Gal) in a rat model. METHODS AND
results40 Wister male adult rats were categorized into 5 groups. Group 1 received normal saline; group 2 was given 100 mg/kg of D-Gal intraperitoneally (IP). The rats in groups 3 to 5 were given D-Gal (100 mg/kg, IP) along with different doses of OLE (20, 40, and 80 mg/kg, respectively) orally. All administrations were performed daily for 8 weeks. 24 h after last treatment motor activity and memory impairment were evaluated. Then, the rats were euthanized and brain samples were collected for evaluating the levels of malondialdehyde (MDA), Brain-Derived Neurotrophic Factor (BDNF), protein carbonyl (PC), glutathione (GSH), glutathione peroxidase (GPX), catalase (CAT), Superoxide dismutase (SOD), Tumor necrosis factor alpha (TNF-α), interleukin 1 beta ( IL-1β), as well as Sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1) gene expression. The results showed that D-Gal significantly reduced motor activity and memory performance (P < 0.05). It also significantly reduced the GPX, CAT and SOD activities, GSH and BDNF levels as well as SIRT1 and PGC1 expression, and, significantly increased PC, MDA TNF-α and IL-1β levels in the brain tissue (P < 0.05). Administration of OLE restored all of the above parameters close to control group.
conclusionThe findings demonstrated that OLE, through its antioxidant and anti-inflammatory properties, improved motor activity, memory impairment, and age-related neurological dysfunction.
Indexed as
Identifiers
39704928What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.